Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARCA Biopharma Inc ABIO

Healthcare Biotechnology
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is... see more

Recent & Breaking News (NDAQ:ABIO)

ARCA biopharma Announces 100th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

Business Wire August 18, 2016

ARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update

Business Wire August 9, 2016

ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update

Business Wire May 11, 2016

ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial

Business Wire April 18, 2016

ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update

Business Wire March 17, 2016

GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient

Business Wire January 12, 2016

2 Micro-Cap Opportunities in Atrial Fibrillation

Accesswire November 30, 2015

ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference

Business Wire November 19, 2015

2 Important Takeaways from ARCA Biopharma's Q3 Results

Accesswire November 18, 2015

ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update

Business Wire November 12, 2015

ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Association Scientific Sessions 2015

Business Wire November 5, 2015

Biotech Pullback: Look to Targeted Therapy Companies

Accesswire October 19, 2015

ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease

Accesswire September 15, 2015

Gencaro(TM) Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to Be Presented at 2015 HFSA Annual Scientific Meeting

Business Wire September 9, 2015

ARCA biopharma to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

Business Wire August 26, 2015

ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments

Business Wire August 11, 2015

Nutritional Supplement Industry Flexes its Muscles as Natural & Pharmaceutical Supplement Products Continue to Hit the Market - Company Prepares for Strong Revenue Growth in 2nd Half of 2015

PR Newswire June 29, 2015

ARCA biopharma Announces Closing of $37 Million Private Placement

Business Wire June 17, 2015

ARCA biopharma Announces $37 Million Private Placement

Business Wire June 11, 2015

ARCA biopharma Receives FDA Fast Track Designation for Gencaro(TM) Atrial Fibrillation Development in a Genetically Targeted Heart Failure Population

Business Wire April 13, 2015